These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23258125)

  • 21. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 22. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
    Bloomgarden ZT
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):439-41. PubMed ID: 24731676
    [No Abstract]   [Full Text] [Related]  

  • 25. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data].
    Sesti G
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):10-6. PubMed ID: 22158422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.
    Lorenz M; Evers A; Wagner M
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4011-8. PubMed ID: 23743288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of type 2 diabetes mellitus with GLP-1 agonists].
    Haluzík M; Urbanová M; Trachta P
    Vnitr Lek; 2011 Apr; 57(4):411-5. PubMed ID: 21612070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists?
    Doggrell SA
    Expert Opin Drug Saf; 2015 Jun; 14(6):801-5. PubMed ID: 25891299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
    Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
    J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
    Monami M; Zannoni S; Pala L; Silverii A; Andreozzi F; Sesti G; Mannucci E
    Int J Cardiol; 2017 Aug; 240():414-421. PubMed ID: 28501352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
    Okerson T; Yan P; Stonehouse A; Brodows R
    Am J Hypertens; 2010 Mar; 23(3):334-9. PubMed ID: 20019672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
    Haluzík M; Trachta P; Mráz M
    Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
    Forst T; Plum-Mörschel L; Weber MM
    Internist (Berl); 2017 Mar; 58(3):293-302. PubMed ID: 28120022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardioprotective effects of glucagon-like peptide 1 receptor agonists].
    Ametov AS; Kamynina LL; Akhmedova ZG
    Kardiologiia; 2014; 54(7):92-6. PubMed ID: 25177820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.